Neuros Medical
Aliso Viejo, US · Delaware corporation · 12 known investors
Neuros Medical is a privately held medical device company that makes the Altius Direct Electrical Nerve Stimulation System for treating chronic post-amputation pain, including phantom limb and residual limb pain. It serves amputee patients and the healthcare professionals who treat them in the United States.
Founders & leadership
DV
David VeinoPresident and CEO
ZS
Zach StassenChief Financial Officer
RJ
Robert J. CentaChief Financial Officer
JJ
Jon J. SnyderDirector, President, Secretary and CEO
Board
JE
WH
William HarringtonBoard director
FA
Fouad AzzamBoard director
CT
MM
Marc-Andre MarcotteBoard director
RB
Randy BanBoard director
CR
Claiborne R. RankinBoard director
JJ
Joseph J. JankowskiBoard director
Investors · 12
Amzak HealthNew York
APERTURE Venture PartnersBoston · $1M – $5M
CWRU Technology VenturesCleveland · $50K – $250K
iSelect FundSt. Louis · $250K – $2M
JobsOhio VenturesColumbus
Jumpstart VenturesCleveland · $500K – $2M
RiverVest Venture PartnersSt. Louis · $500K – $3M
US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
EQT Life SciencesreportedLuxembourg · $11M – $66M
Osage University PartnersreportedBala Cynwyd
Sectoral Asset ManagementreportedMontreal
Signet Healthcare PartnersreportedNew York · $10M – $50Mvia Joyce Erony · board
Reported raises · per SEC filings
Form D private placements$148.4M disclosed across 7 of 9 rounds · 2016–2025
▶$56MraisedAug 2025 · 28 investors · BiotechnologyRule 506(b)
▶$56MraisedAug 2025 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David VeinoExecutive Officer, Director
- Joyce EronyDirector
- William HarringtonDirector
- Fouad AzzamDirector
- Zach StassenExecutive Officer
- Casey TanseyDirector
- Marc-Andre MarcotteDirector
- Randy BanDirector
- Offering amount
- $65M
- Amount sold
- $56M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedSep 2023 · 41 investors · BiotechnologyRule 506(b)
▶$20MraisedSep 2023 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William HarringtonDirector
- Marc-Andre MarcotteDirector
- Casey TanseyDirector
- Anthony NataleDirector
- Thomas C. WilderExecutive Officer, Director
- Joyce EronyDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.2MraisedDec 2022 · 40 investors · BiotechnologyRule 506(b)
▶$8.2MraisedDec 2022 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joyce EronyDirector
- Thomas C. WilderExecutive Officer, Director
- William HarringtonDirector
- Anthony NataleDirector
- Casey TanseyDirector
- Marc-Andre MarcotteDirector
- Offering amount
- $10M
- Amount sold
- $8.2M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$37MraisedNov 2020 · 24 investors · BiotechnologyRule 506(b)
▶$37MraisedNov 2020 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas C. WilderExecutive Officer, Director
- Casey TanseyDirector
- William HarringtonDirector
- Anthony NataleDirector
- Marc-Andre MarcotteDirector
- Joyce EronyDirector
- Offering amount
- $42.8M
- Amount sold
- $37M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedJun 2020 · 5 investors · BiotechnologyRule 506(b)
▶$2.2MraisedJun 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William HarringtonDirector
- Casey TanseyDirector
- Thomas C. WilderExecutive Officer, Director
- Anthony NataleDirector
- Offering amount
- $5.5M
- Amount sold
- $2.2M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedOct 2019 · 4 investors · BiotechnologyRule 506(b)
▶$2.4MraisedOct 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas C. WilderExecutive Officer, Director
- William HarringtonDirector
- Casey TanseyDirector
- Anthony NataleDirector
- Offering amount
- $9.2M
- Amount sold
- $2.4M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedAug 2017 · 55 investors · BiotechnologyRule 506(c)
▶Undisclosed amountofferedAug 2017 · 55 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Anthony NataleDirector
- William HarringtonDirector
- Casey TanseyDirector
- Jon J. SnyderExecutive Officer, Director
- Alan KaganovDirector
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$22.6MraisedAug 2017 · 27 investors · BiotechnologyRule 506(c)
▶$22.6MraisedAug 2017 · 27 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Anthony NataleDirector
- Alan KaganovDirector
- William HarringtonDirector
- Jon J. SnyderExecutive Officer, Director
- Casey TanseyDirector
- Offering amount
- $22.7M
- Amount sold
- $22.6M
- Minimum investment
- $16.7K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapRf Surgical28 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Topera28 shared keywordsAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Boston Scientific15 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Noctrix Health13 shared keywordsNoctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes. The company targets patients living with chronic conditions such as restless legs syndrome, offering prescription-grade therapy through medical devices.
Companies competing with Neuros Medical for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Neuros Medical do?
- Neuros Medical is a privately held medical device company that makes the Altius Direct Electrical Nerve Stimulation System for treating chronic post-amputation pain, including phantom limb and residual limb pain. It serves amputee patients and the healthcare professionals who treat them in the United States.
- Who are Neuros Medical's investors?
- Neuros Medical's investors include Amzak Health, APERTURE Venture Partners, CWRU Technology Ventures, iSelect Fund, JobsOhio Ventures, Jumpstart Ventures, RiverVest Venture Partners, US Venture Partners and 4 more.
- How much funding has Neuros Medical raised?
- Neuros Medical has disclosed $148.4M raised across 7 of its 9 known rounds.
- Where is Neuros Medical headquartered?
- Neuros Medical is headquartered in Aliso Viejo, US.